Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA.
Am J Kidney Dis. 2013 Aug;62(2):312-21. doi: 10.1053/j.ajkd.2013.02.375. Epub 2013 May 4.
Hispanic patients undergoing long-term dialysis experience better survival compared with non-Hispanic whites. It is unknown whether this association differs by age, has changed over time, or is due to differential access to kidney transplantation.
National retrospective cohort study.
SETTING & PARTICIPANTS: Using the US Renal Data System, we identified 615,618 white patients 18 years or older who initiated dialysis therapy between January 1, 1995, and December 31, 2007.
Hispanic ethnicity (vs non-Hispanic whites), year of end-stage renal disease incidence, age (as potential effect modifier).
All-cause and cause-specific mortality.
We found that Hispanics initiating dialysis therapy experienced lower mortality, but age modified this association (P < 0.001). Compared with non-Hispanic whites, mortality in Hispanics was 33% lower at ages 18-39 years (adjusted cause-specific HR [HRcs], 0.67; 95% CI, 0.64-0.71) and 40-59 years (HRcs, 0.67; 95% CI, 0.66-0.68), 19% lower at ages 60-79 years (HRcs, 0.81; 95% CI, 0.80-0.82), and 6% lower at 80 years or older (HRcs, 0.94; 95% CI, 0.91-0.97). Accounting for the differential rates of kidney transplantation, the associations were attenuated markedly in the younger age strata; the survival benefit for Hispanics was reduced from 33% to 10% at ages 18-39 years (adjusted subdistribution-specific HR [HRsd], 0.90; 95% CI, 0.85-0.94) and from 33% to 19% among those aged 40-59 years (HRsd, 0.81; 95% CI, 0.80-0.83).
Inability to analyze Hispanic subgroups that may experience heterogeneous mortality outcomes.
Overall, Hispanics experienced lower mortality, but differential access to kidney transplantation was responsible for much of the apparent survival benefit noted in younger Hispanics.
接受长期透析治疗的西班牙裔患者的存活率高于非西班牙裔白人。目前尚不清楚这种关联是否因年龄而异、随时间变化而变化,或者是否是由于接受肾移植的机会不同所致。
全国回顾性队列研究。
我们使用美国肾脏数据系统,确定了 1995 年 1 月 1 日至 2007 年 12 月 31 日期间年龄在 18 岁或以上开始透析治疗的 615618 名白人患者。
西班牙裔种族(与非西班牙裔白人相比)、终末期肾脏疾病发病年份、年龄(可能的效应修饰因素)。
全因和病因特异性死亡率。
我们发现,接受透析治疗的西班牙裔患者的死亡率较低,但年龄改变了这种关联(P<0.001)。与非西班牙裔白人相比,18-39 岁年龄组的西班牙裔患者死亡率低 33%(校正病因特异性 HR [HRcs],0.67;95%CI,0.64-0.71),40-59 岁年龄组的死亡率低 40%(HRcs,0.67;95%CI,0.66-0.68),60-79 岁年龄组的死亡率低 19%(HRcs,0.81;95%CI,0.80-0.82),80 岁或以上年龄组的死亡率低 6%(HRcs,0.94;95%CI,0.91-0.97)。考虑到肾移植的差异率,在年龄较小的亚组中,这种关联明显减弱;在 18-39 岁年龄组,西班牙裔患者的生存获益从 33%降至 10%(校正亚分布特异性 HR [HRsd],0.90;95%CI,0.85-0.94),在 40-59 岁年龄组,生存获益从 33%降至 19%(HRsd,0.81;95%CI,0.80-0.83)。
无法分析可能存在不同死亡率结局的西班牙裔亚组。
总体而言,西班牙裔患者的死亡率较低,但接受肾移植的机会不同,这在很大程度上解释了年轻西班牙裔患者的明显生存获益。